Evidence map›Paper›PMID 34740617›Full record

ArticleCellular and molecular gastroenterology and hepatology2022

A Promising Genetic Target for a Deadly Disease: Single Immunoglobulin Interleukin 1 (SIGIRR) Mutations in Necrotizing Enterocolitis.

Misty Good, Camilia R Martin

Open access · goldAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Misty GoodDivision of Newborn Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri.
Camilia R MartinDepartment of Neonatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: cmartin1@bidmc.harvard.edu.
Harvard University · USWashington University in St. Louis · US

Funding

Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitisR01DK124614 · NIDDK · WASHINGTON UNIVERSITY · PI GOOD, MISTY L, PETERS, DAVID GERARD · 2021 to 2024
$2.5M
Neonatal gut-on-a-chip platform for high content drug testing and precision medicineR01HD105301 · NICHD · WASHINGTON UNIVERSITY · PI GOOD, MISTY L, MAGNESS, SCOTT T · 2021 to 2024
$2.4M
Phenotypic Driven Growth Trajectories in Very Preterm Infants to Define Nutritionally Mediated Health Outcomes and Modifiable TargetsR01HD106359 · NICHD · YALE UNIVERSITY · PI MARTIN, CAMILIA R, TAYLOR, SARAH N · 2021 to 2025
$2.1M
Modulation of the Intestinal Immune Response in Necrotizing EnterocolitisR01DK118568 · NIDDK · WASHINGTON UNIVERSITY · PI GOOD, MISTY L · 2018 to 2022
$1.8M
NICHD NIH HHS R01 HD105301NICHD NIH HHS R01 HD106359NIDDK NIH HHS R01 DK118568NIDDK NIH HHS R01 DK124614
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Enterocolitis, NecrotizingHumansImmunoglobulinsInterleukin-1MutationToll-Like Receptor 4ImmunoglobulinsInterleukin-1Toll-Like Receptor 4

Identifiers

PMID34740617
PMCPMC8776998
OpenAlexW3208896734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.